171 related articles for article (PubMed ID: 33854822)
1. Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas.
Yin A; Shang Z; Etcheverry A; He Y; Aubry M; Lu N; Liu Y; Mosser J; Lin W; Zhang X; Dong Y
Oncoimmunology; 2021 Mar; 10(1):1902071. PubMed ID: 33854822
[TBL] [Abstract][Full Text] [Related]
2. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.
Liang BB; Wang YH; Huang JJ; Lin S; Mao GC; Zhou ZJ; Yan WJ; Shan CY; Wu HZ; Etcheverry A; He YL; Liu FF; Kang HF; Yin AA; Zhang SQ
CNS Neurosci Ther; 2024 Apr; 30(4):e14465. PubMed ID: 37830163
[TBL] [Abstract][Full Text] [Related]
4. A five-CpG signature of microRNA methylation in non-G-CIMP glioblastoma.
Kang EM; Yin AA; He YL; Chen WJ; Etcheverry A; Aubry M; Barnholtz-Sloan J; Mosser J; Zhang W; Zhang X
CNS Neurosci Ther; 2019 Sep; 25(9):937-950. PubMed ID: 31016891
[TBL] [Abstract][Full Text] [Related]
5. Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Wang J; Zhang M; Liu YF; Yao Y; Ji YS; Etcheverry A; Chen K; Song BQ; Lin W; Yin A; He YL
Epigenomics; 2022 Oct; 14(20):1233-1247. PubMed ID: 36444681
[TBL] [Abstract][Full Text] [Related]
6. A novel prognostic six-CpG signature in glioblastomas.
Yin AA; Lu N; Etcheverry A; Aubry M; Barnholtz-Sloan J; Zhang LH; Mosser J; Zhang W; Zhang X; Liu YH; He YL
CNS Neurosci Ther; 2018 Mar; 24(3):167-177. PubMed ID: 29350455
[TBL] [Abstract][Full Text] [Related]
7. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
8. A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas.
Li B; Wang J; Liu F; Li R; Hu W; Etcheverry A; Aubry M; Mosser J; Yin A; Zhang X; Wu Y; Chen K; He Y; Wang L
J Oncol; 2022; 2022():6345160. PubMed ID: 35712126
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis of novel hypomethylation and gene expression signatures in glioblastomas.
Yin A; Etcheverry A; He Y; Aubry M; Barnholtz-Sloan J; Zhang L; Mao X; Chen W; Liu B; Zhang W; Mosser J; Zhang X
Oncotarget; 2017 Oct; 8(52):89607-89619. PubMed ID: 29163774
[TBL] [Abstract][Full Text] [Related]
10. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.
de Souza CF; Sabedot TS; Malta TM; Stetson L; Morozova O; Sokolov A; Laird PW; Wiznerowicz M; Iavarone A; Snyder J; deCarvalho A; Sanborn Z; McDonald KL; Friedman WA; Tirapelli D; Poisson L; Mikkelsen T; Carlotti CG; Kalkanis S; Zenklusen J; Salama SR; Barnholtz-Sloan JS; Noushmehr H
Cell Rep; 2018 Apr; 23(2):637-651. PubMed ID: 29642018
[TBL] [Abstract][Full Text] [Related]
11. A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide.
Chai RC; Chang YZ; Wang QW; Zhang KN; Li JJ; Huang H; Wu F; Liu YQ; Wang YZ
Front Genet; 2019; 10():910. PubMed ID: 31611911
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtypes of glioma identified by genome-wide methylation profiling.
Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
[TBL] [Abstract][Full Text] [Related]
13. Identification of subsets of
Li KK; Shi ZF; Malta TM; Chan AK; Cheng S; Kwan JSH; Yang RR; Poon WS; Mao Y; Noushmehr H; Chen H; Ng HK
Neurooncol Adv; 2019; 1(1):vdz015. PubMed ID: 31667475
[TBL] [Abstract][Full Text] [Related]
14. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
15. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
16. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Turcan S; Rohle D; Goenka A; Walsh LA; Fang F; Yilmaz E; Campos C; Fabius AW; Lu C; Ward PS; Thompson CB; Kaufman A; Guryanova O; Levine R; Heguy A; Viale A; Morris LG; Huse JT; Mellinghoff IK; Chan TA
Nature; 2012 Feb; 483(7390):479-83. PubMed ID: 22343889
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas.
Li J; Taich ZJ; Goyal A; Gonda D; Akers J; Adhikari B; Patel K; Vandenberg S; Yan W; Bao Z; Carter BS; Wang R; Mao Y; Jiang T; Chen CC
Oncotarget; 2014 Sep; 5(17):7342-56. PubMed ID: 25277177
[TBL] [Abstract][Full Text] [Related]
19. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
20. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Noushmehr H; Weisenberger DJ; Diefes K; Phillips HS; Pujara K; Berman BP; Pan F; Pelloski CE; Sulman EP; Bhat KP; Verhaak RG; Hoadley KA; Hayes DN; Perou CM; Schmidt HK; Ding L; Wilson RK; Van Den Berg D; Shen H; Bengtsson H; Neuvial P; Cope LM; Buckley J; Herman JG; Baylin SB; Laird PW; Aldape K;
Cancer Cell; 2010 May; 17(5):510-22. PubMed ID: 20399149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
